These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

913 related items for PubMed ID: 35910212

  • 1. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
    Xu S, Liu D, Chang T, Wen X, Ma S, Sun G, Wang L, Chen S, Xu Y, Zhang H.
    Front Genet; 2022; 13():938259. PubMed ID: 35910212
    [Abstract] [Full Text] [Related]

  • 2. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
    Zhang L, Di L, Liu J, Lei X, Gu M, Zhang W, Wang Y.
    Front Genet; 2023; 14():1039813. PubMed ID: 36755568
    [Abstract] [Full Text] [Related]

  • 3. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S, Bai H, Fei S, Miao B.
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [Abstract] [Full Text] [Related]

  • 4. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y, Zhang Q, Zhang H, Kong F.
    Funct Integr Genomics; 2023 Jan 14; 23(1):38. PubMed ID: 36640225
    [Abstract] [Full Text] [Related]

  • 5. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
    Ren L, Yang X, Wang W, Lin H, Huang G, Liu Z, Pan J, Mao X.
    Front Genet; 2023 Jan 14; 14():1096783. PubMed ID: 36911392
    [Abstract] [Full Text] [Related]

  • 6. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z, Lu J, Chen A, Zheng X, Wu M, Tan Z, Xie J.
    Biomolecules; 2022 Dec 16; 12(12):. PubMed ID: 36551318
    [Abstract] [Full Text] [Related]

  • 7. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
    Chen Y, Hu W, Wei X, Zhang L, Shao Y, Tian J, Wang D, Wu B.
    Transl Androl Urol; 2023 Apr 28; 12(4):622-641. PubMed ID: 37181235
    [Abstract] [Full Text] [Related]

  • 8. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N, Hu Y, Wang S, Xu Q, Jiao X, Wang Y, Yan L, Cao H, Shao F.
    Sci Rep; 2024 Jan 05; 14(1):624. PubMed ID: 38182642
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bioinformatics analysis and experimental validation of m6A and cuproptosis-related lncRNA NFE4 in clear cell renal cell carcinoma.
    Feng R, Li H, Meng T, Fei M, Yang C.
    Discov Oncol; 2024 May 26; 15(1):187. PubMed ID: 38797784
    [Abstract] [Full Text] [Related]

  • 11. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y, Jiang J.
    Cancer Biomark; 2023 May 26; 37(1):13-26. PubMed ID: 37005878
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y, Zhang Q, Liu F, Quan J.
    Front Immunol; 2022 May 26; 13():1027449. PubMed ID: 36451815
    [Abstract] [Full Text] [Related]

  • 14. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X, Ye Z, Xiao G, He T.
    Comput Biol Med; 2023 Jun 26; 159():106905. PubMed ID: 37060773
    [Abstract] [Full Text] [Related]

  • 15. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M, Mu J, Wang J, Zhou Q, Wang J.
    Front Oncol; 2022 Jun 26; 12():961213. PubMed ID: 35965536
    [Abstract] [Full Text] [Related]

  • 16. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Yang L, Yu J, Tao L, Huang H, Gao Y, Yao J, Liu Z.
    Front Genet; 2022 Jun 26; 13():947551. PubMed ID: 35938003
    [Abstract] [Full Text] [Related]

  • 17. Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma.
    Huili Y, Nie S, Zhang L, Yao A, Liu J, Wang Y, Wang L, Cao F.
    Front Genet; 2022 Jun 26; 13():958547. PubMed ID: 36072656
    [Abstract] [Full Text] [Related]

  • 18. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F, Lin H, Su Q, Li C.
    World J Surg Oncol; 2022 Sep 01; 20(1):275. PubMed ID: 36050740
    [Abstract] [Full Text] [Related]

  • 19. Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma.
    Shi Y, Sheng P, Guo M, Chen K, Zhou H, Wu M, Li W, Li B.
    Front Genet; 2023 Sep 01; 14():1100909. PubMed ID: 37470034
    [Abstract] [Full Text] [Related]

  • 20. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
    Li P, Li J, Wen F, Cao Y, Luo Z, Zuo J, Wu F, Li Z, Li W, Wang F.
    Front Oncol; 2022 Sep 01; 12():966920. PubMed ID: 36276132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.